Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

VIA/VILI is more suitable for cervical cancer prevention in Chinese poverty-stricken region: a health economic evaluation.

Xie Y, Tan X, Shao H, Liu Q, Tou J, Zhang Y, Luo Q, Xiang Q.

BMC Public Health. 2017 Jan 25;17(1):118. doi: 10.1186/s12889-017-4054-9.

2.

Epidemiology of HPV Genotypes among HIV Positive Women in Kenya: A Systematic Review and Meta-Analysis.

Menon S, Wusiman A, Boily MC, Kariisa M, Mabeya H, Luchters S, Forland F, Rossi R, Callens S, Vanden Broeck D.

PLoS One. 2016 Oct 20;11(10):e0163965. doi: 10.1371/journal.pone.0163965.

3.

The Prevalence of Cervical Human Papillomavirus Infection and the Most At-risk Genotypes Among Iranian Healthy Women: A Systematic Review and Meta-analysis.

Malary M, Moosazadeh M, Hamzehgardeshi Z, Afshari M, Moghaddasifar I, Afsharimoghaddam A.

Int J Prev Med. 2016 May 4;7:70. doi: 10.4103/2008-7802.181756. Review.

4.

Human papillomavirus related cervical cancer and anticipated vaccination challenges in Ethiopia.

Gebremariam T.

Int J Health Sci (Qassim). 2016 Jan;10(1):137-43. Review.

5.

Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology.

Lee M, Chang MY, Shin HY, Shin E, Hong SW, Kim KM, Chay DB, Cho H, Kim JH.

Medicine (Baltimore). 2016 Jan;95(3):e2425. doi: 10.1097/MD.0000000000002425.

6.
7.

Anti-cancer vaccines - a one-hit wonder?

Liu JK.

Yale J Biol Med. 2014 Dec 12;87(4):481-9. Review.

8.

Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review.

Woods R Sr, O'Regan EM, Kennedy S, Martin C, O'Leary JJ, Timon C.

World J Clin Cases. 2014 Jun 16;2(6):172-93. doi: 10.12998/wjcc.v2.i6.172. Review.

9.

What do women with gynecologic cancer know about HPV and their individual disease? A pilot study.

Pils S, Joura EA, Winter MP, Shrestha A, Jaeger-Lansky A, Ott J.

BMC Cancer. 2014 May 30;14:388. doi: 10.1186/1471-2407-14-388.

10.

Community-based interventions to improve HPV vaccination coverage among 13- to 15-year-old females: measures implemented by local governments in Japan.

Fujiwara H, Takei Y, Ishikawa Y, Saga Y, Machida S, Taneichi A, Suzuki M.

PLoS One. 2013 Dec 16;8(12):e84126. doi: 10.1371/journal.pone.0084126.

11.

Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?

van Bogaert Lj.

Ann Med Health Sci Res. 2013 Jul;3(3):306-12. doi: 10.4103/2141-9248.117924. Review.

12.

Factors associated With Medicaid providers' recommendation of the HPV vaccine to low-income adolescent girls.

Bynum SA, Staras SA, Malo TL, Giuliano AR, Shenkman E, Vadaparampil ST.

J Adolesc Health. 2014 Feb;54(2):190-6. doi: 10.1016/j.jadohealth.2013.08.006.

13.

Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects.

Wigle J, Coast E, Watson-Jones D.

Vaccine. 2013 Aug 20;31(37):3811-7. doi: 10.1016/j.vaccine.2013.06.016. Review.

14.

Selective virus detection in complex sample matrices with photonic crystal optical cavities.

Pal S, Yadav AR, Lifson MA, Baker JE, Fauchet PM, Miller BL.

Biosens Bioelectron. 2013 Jun 15;44:229-34. doi: 10.1016/j.bios.2013.01.004.

15.

Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs.

Lee HJ, Hur YK, Cho YD, Kim MG, Lee HT, Oh YK, Kim YB.

PLoS One. 2012;7(11):e50296. doi: 10.1371/journal.pone.0050296.

16.

Human papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active women.

Tsu V, Murray M, Franceschi S.

Br J Cancer. 2012 Oct 23;107(9):1445-50. doi: 10.1038/bjc.2012.404. Review.

17.

Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck.

Psyrri A, Sasaki C, Vassilakopoulou M, Dimitriadis G, Rampias T.

Head Neck Pathol. 2012 Jul;6 Suppl 1:S121-8. doi: 10.1007/s12105-012-0361-8. Review.

18.

Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study).

Orlando G, Tanzi E, Chatenoud L, Gramegna M, Rizzardini G; VALHIDATE Study Group..

BMC Cancer. 2012 May 30;12:204. doi: 10.1186/1471-2407-12-204.

19.

Small molecule inhibitors of the HPV16-E6 interaction with caspase 8.

Yuan CH, Filippova M, Tungteakkhun SS, Duerksen-Hughes PJ, Krstenansky JL.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):2125-9. doi: 10.1016/j.bmcl.2011.12.145.

20.

Efficient production of HIV-1 virus-like particles from a mammalian expression vector requires the N-terminal capsid domain.

Jalaguier P, Turcotte K, Danylo A, Cantin R, Tremblay MJ.

PLoS One. 2011;6(11):e28314. doi: 10.1371/journal.pone.0028314.

Items per page

Supplemental Content

Support Center